Frazier Life Sciences XI, L.P.

CIK: 0001911592

Transaction Breakdown

Open Market Buys (P)1 (20.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)0 (0.0%)

Compensation grants

Other (G, F, J, C, D, …)4 (80.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

ATTO

Attovia Therapeutics, Inc.

10% Owner

Discretionary Trading P&L

Holdings

Transaction History (5 total)

ATTO
Attovia Therapeutics, Inc.
Aug 6, 2026
Conversion(C)
Direct
1.7M shares-
ATTO
Attovia Therapeutics, Inc.
Aug 6, 2026
Conversion(C)
Direct
1.6M shares-
ATTO
Attovia Therapeutics, Inc.
Aug 6, 2026
Conversion(C)
Direct
1.2M shares-
ATTO
Attovia Therapeutics, Inc.
Aug 6, 2026
Conversion(C)
Direct
961.3K shares-
ATTO
Attovia Therapeutics, Inc.
Aug 6, 2026
Purchase(P)
Direct
588.2K shares at avg. $17.00$10.0M

		Type	Shares	Price		Ownership
Aug 6, 2026	ATTO Attovia Therapeutics, Inc.	Conversion(C)	1,749,192	-	$0	Direct
Aug 6, 2026	ATTO Attovia Therapeutics, Inc.	Conversion(C)	1,590,175	-	$0	Direct
Aug 6, 2026	ATTO Attovia Therapeutics, Inc.	Conversion(C)	1,189,940	-	$0	Direct
Aug 6, 2026	ATTO Attovia Therapeutics, Inc.	Conversion(C)	961,322	-	$0	Direct
Aug 6, 2026	ATTO Attovia Therapeutics, Inc.	Purchase(P)	588,235	$17.00	$9,999,995	Direct

1-5 of 5 transactions

About Frazier Life Sciences XI, L.P.

Frazier Life Sciences XI, L.P. (SEC CIK 0001911592) files insider reports with the SEC as 10% Owner of Attovia Therapeutics, Inc. (ATTO).

Signal8 holds 2 ownership filings by Frazier Life Sciences XI, L.P. (1 Form 3, 1 Form 4), filed between Aug 4, 2026 and Aug 6, 2026. Those filings report 5 transactions, the latest on Aug 6, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Frazier Life Sciences XI, L.P.'s filings is in PALO ALTO, CA.

Recent filings by Frazier Life Sciences XI, L.P.

Aug 6, 2026: Conversions of ATTO shares (4 lines, Form 4, code C).
Aug 6, 2026: Open-market purchase of ATTO shares (Form 4, code P).

Other insiders filing for Attovia Therapeutics, Inc. (ATTO)

Fu Tao, President and CEO
Chan Steven, Chief Financial Officer
WALSH COLIN, Director
GOLDMAN SACHS GROUP INC, Officer
Deep Track Biotechnology Master Fund, Ltd., 10% Owner
venBio Global Strategic Fund IV, L.P., 10% Owner

How to read Form 4 transaction codes